Statin therapy is a cornerstone of secondary prevention, with a wealth of data to support their use in nearly all patients after acute myocardial infarction (AMI), regardless of age, sex, or even baseline low-density lipoprotein cholesterol (LDL-C) levels. [1] [2] [3] As such, prescription of statins at discharge is both a Class 1(A) recommendation in the AMI guidelines [4] [5] and a performance measure for quality AMI care. 6 Importantly, clinical trials have shown that more potent statins reduce morbidity and mortality after AMI more effectively than less potent statins. [7] [8] [9] [10] [11] This was reflected in the 2013 cholesterol guidelines, which recommended high-intensity statins to all patients with established atherosclerotic cardiovascular disease. 12 Thus, while it is critical that all eligible patients be discharged on a statin after AMI, it is also important to discharge patients on high doses of potent statins to maximize their benefit in reducing recurrent ischemic events.
While the prescription of statins in any dose after AMI has been evaluated, [13] [14] studies have not examined rates of statin intensification and maximization. Understanding the prevalence and variations in these important strategies can highlight opportunities to optimize secondary prevention in this high-risk patient group. To address these gaps in knowledge, we examined the rates of statin initiation, intensification (among patients who arrived on a submaximal statin), and maximization among over 4000 post-AMI patients from 24 U.S. hospitals and evaluated patient-and site-level factors associated with more intensive statin use.
Methods

Study population and protocol
Details regarding the study design, patient selection, site characteristics and follow-up assessments of the TRIUMPH study have been previously published. 15 Briefly, 4340 patients from 24 U.S. hospitals were enrolled into the TRIUMPH registry between April 2005 and high doses of potent statins to maximize their benefit in reducing recurrent ischem em mic ic c e eve v vent nt nts. s. s
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Definition of statin initiation, intensification, and maximization
Initiation of statin therapy was defined as statin prescription on discharge in a patient who was not on a statin at admission. Among patients who arrived on a sub-maximal statin (i.e., a statin with expected LDL-C lowering of <50%), intensification of statin therapy was defined as either of the following: 1) increase in dose of current statin or 2) change in statin from a lower potency to a higher potency statin that was expected to result in an additional 10% LDL-C lowering ( Table 1) . Maximization of statin therapy was defined as discharge on a statin with a 50% or greater expected reduction in LDL-C 12, 16 (i.e., atorvastatin 80mg or rosuvastatin 20-40mg daily).
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Statistical analysis
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Covariates for the models included demographics, standard cardiac risk factors, severity of MI, absence of LDL-C assessment during hospitalization, and baseline LDL-C level (acquired during hospitalization). Site was entered as a random effect to account for clustering of patients within hospitals (with an exchangeable within-hospital correlation structure), and site-level variation was explored with a median rate ratio (MRR), which estimates the average relative difference in risk ratios of two hypothetical patients being started on a statin/intensified with therapy if enrolled at two different sites. Cubic splines were considered for all continuous variables to check for non-linear relationships between these covariates and the outcome. Additionally, as the data to intensify and maximize statin therapy among AMI patients with very low LDL-C levels are not as clear, we performed sensitivity analyses for intensification and maximization, excluding patients with LDL-C levels <70 mg/dL. For the maximization analysis, we also performed a sensitivity analysis by excluding 4 hospitals with formularies that favored simvastatin, as this may have affected the rates of prescription of maximally potent statins.
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Results
Study population
The patient characteristics of the 4271 patients enrolled in TRIUMPH who were discharged alive and had no documented contraindications to statin therapy are shown in Table 2 . The mean age of patients was 59 years, 67% were male, and 31% had diabetes. Forty-three percent of patients presented with ST-elevations, and 92% underwent invasive management of their AMI. The analytic cohorts are outlined in Figure 1 . Among the 4271 patients discharged alive without contraindications to statin therapy, 2776 reported that they were not taking a statin at admission (statin initiation analytic cohort). Of the 1495 patients (35%) who arrived on a statin, we did not have adequate drug or dose information on 125 patients at admission to be able to categorize the intensity of their statin therapy. An additional 140 patients were taking a maximal dose of statin at admission, leaving 1230 patients eligible for the statin intensification cohort. All patients discharged alive without contraindications for statin therapy were considered eligible for the statin maximization analysis.
Statin prescription patterns
Of the 2776 patients who were statin naïve on presentation for their AMI and had no contraindications to statin therapy, 2411 patients (87%) were started on a statin during hospitalization, most commonly atorvastatin (47%) or simvastatin (39%). In a hierarchical, multivariable model adjusted for patients' sociodemographic and clinical characteristics, there was virtually no site-level variability in statin initiation, with an MRR of 1.02 (95% CI 1.01-),
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In regard to rates of aggressive lipid management across hospitals, the rates of intensification and maximization were highly correlated among hospitals (r=0.81, p<0.001),
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Patient factors associated with statin prescribing patterns
In the hierarchical multivariable models, there were few patient factors that were associated with a greater likelihood of statin initiation, intensification, or maximization (Supplemental Table 2 ).
Patients with lower LDL-C levels were less likely to be started on a statin, were less likely to have their statin dose intensified, and were less likely to be discharged on a maximal statin Table 2 ).
Discussion
In a large, multicenter, contemporary prospective cohort of AMI patients, we found that statin initiation is very common, with 87% of statin naïve patients being started on a statin during hospitalization. Furthermore, there was no site-level variation in statin initiation, indicating that practice patterns for starting patients on statins during AMI were uniform across all hospitals studied. However, among patients who were already taking a statin at the time of AMI, intensification of the statin occurred infrequently, in only 26% of patients, with modest site-level have their statin dose intensified, and were less likely to be discharged on a max xim im mal al a s sta ta ati ti tin n n
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pres s sen e ted with h S S ST--el el le ev vat at atio io ions ns ns w w wer ere e e n ne nea ar arl ly 50% 0% 0% m mor ore li ik ike el ely y y to o o h ha a ave e e th th hei ei e r st stat at atin in in i int nt ten en ensi si sifi fi variability. Moreover, statin maximization occurred in only 23% of patients with substantial sitelevel variability, including 2 hospitals maximizing therapy in none of their patients, while 2 hospitals maximized statins in more than half of their patients. The low rates and substantial variation in the practice of intensifying and maximizing statin therapy may be a target for quality improvement, particularly given the evidence of greater benefit with more potent statin therapy after AMI 7-11 and the updated cholesterol guidelines that recommend high-intensity statins in all AMI patients. 12 A key finding of our study is that higher LDL-C levels and ST-elevations on admission were each associated with a substantially higher likelihood of intensive statin therapy (i.e., more intensification and maximization). This likely reflects a belief that these patients are at greatest risk of recurrent ischemic events and, thus, most likely to benefit from more intense statin therapy. While targeting intensive secondary prevention strategies to the patients most likely to benefit is reasonable and appropriate, there is no compelling evidence that there is a differential effect of statin therapy according to either the type of MI (i.e. STEMI vs. NSTEMI) or baseline LDL levels. [1] [2] [3] Furthermore, while high baseline LDL-C levels are associated with higher risk of adverse events among patients with stable coronary disease and patients without known disease, this relationship has not been demonstrated among patients with an AMI and may actually be reversed in the acute setting. 18 This likely results from a combination of factors relating to acute changes in LDL-C levels as an acute phase reactant and lead-time bias (i.e., patients with low LDL-C levels who present with an AMI despite this favorable lipid profile carry some unmeasured risk factors that makes them high-risk, despite a low LDL-C). This finding suggests that educating clinicians about the benefits of intensive statin therapy and constructing performance measures that emphasize statin maximization in all eligible AMI patients may ntensification and maximization). This likely reflects a belief that these patients s ar are e e a at t g g gre re reat at ates est t isk of recurrent ischemic events and, thus, most likely to benefit from more intense statin h her er rap ap apy y. y. W W Wh hi hil l le t tar ar arg ge geting intensive secondary prev ev eve en ntion strategie es s s to t the he he p patients most likely to b be en ne nefit is reaso son na ab b ble e a a and d d ap ap appr pr pro op opri ri ia a at te te, th the ere i is no co co comp p pel el lli lin n ng e evi vide de enc nce e th that at t t the he here re i i is s s a a a di di diff f fe er eren en nti i ia al improve patient care and outcomes.
Our findings both support and extend the prior literature on patterns of statin use after AMI. Several prior studies evaluated lipid-lowering therapy in patients after AMI but focused on absolute rates of treatment with any statin dose, rather than the intensity of statin therapy [13] [14] In an analysis of patients with acute coronary syndromes discharged from 344 hospitals participating in Get With The Guidelines registry from 2005-2009, 89% of eligible patients were discharged on some statin, but only 38% of statin prescriptions at discharge were for intensive statin therapy, as defined by an expected LDL-C lowering of >50%. 16 In a small sub-study of 788 patients from 41 hospitals within the Get With The Guidelines registry, 84% of statin naïve patients were started on statin therapy during their hospitalization, with diabetes mellitus, peripheral vascular disease, prior stroke, prior heart failure, prior revascularization, and a lower LDL-C being associated with a lower likelihood of statin initiation. Of patients with LDL-C >100 mg/dL and not on intensive statin therapy at admission, only 37% had their statin intensified during hospitalization. 19 Our study supports these prior analyses by demonstrating high rates of statin initiation but low rates of statin intensification and maximization. Our study substantially extends the existing literature by examining patient-and site-level factors associated with intensification and maximization. Finding large variability in the use of intensive statin therapy, even after adjusting for patient factors and LDL-C, supports the creation of system-level interventions to improve the use of the more effective secondary prevention strategies with intensive statin therapy, including the potential use of maximal statin therapy as a quality metric in quality improvement registries, such as the ACTION-Get with the Guidelines program.
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given the well-documented challenges of health care transition and outpatient up-titration of statins, 19 there seem to be few valid reasons not to start a patient on intensive statin therapy prior to discharge. Finally, there may be cost or formulary reasons for lower rates of intensification or maximization, as we found lower rates of statin maximization at the 4 VA or county hospitals with formularies that favored simvastatin use. However, after excluding the 4 hospitals with more restricted formularies, the rate of maximization only increased to 27%, indicating that formulary was not the most important driver of a lack of intensification or maximization.
Furthermore, we found that 45% of patients were discharged on atorvastatin or rosuvastatin, which were branded drugs at the time of the study, and an additional 35% of patients were discharged on simvastatin, which became generic half-way through TRIUMPH. There is typically little cost difference between a high dose and a low dose of the same statin, and given that most patients were already on potent statins, the suboptimal intensification and maximization of statins highlights an important potential opportunity to improve care.
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Our study should be interpreted in the context of the following potential limitations. First, while our analysis included 24 hospitals from rural, suburban, and urban sites across the U.S., and the study participants had a broad range of socioeconomic and demographic characteristics, this represents only a small subset of U.S. practice. Replicating these analyses in a larger sample of hospitals would further ensure the generalizability of our findings and could provide further insight into the characteristics of hospitals that influence choice of statin at discharge. Second, we categorized statin potency based on expected LDL-C reduction and defined intensification as a movement to a higher category of statin potency (or an increase in dose). While this strategy was necessary to capture intensification of statin therapy when patients were changed to different medications, it is not explicitly known that a higher category of expected LDL-C reduction would correspond to improved outcomes. While the effect of statins on LDL-C and on reducing recurrent ischemic events are congruent, it is possible that other aspects of statins' efficacy in reducing ischemic events may vary among different statins and are not directly related to their ability to lower LDL-C. Finally, although studies have demonstrated that intensive statin therapy is superior to moderate statin therapy in reducing morbidity and mortality after AMI, 7-11 an explicit strategy of statin intensification or maximization has not been evaluated.
Conclusions
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